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Background
Currently available, second generation antipsychotics
interact with dopamine and serotonin receptors presenting
less extrapyramidal symptoms and better tolerability in the
elderly. Safety data gathered until today show that adverse
events is one of the major reasons leading to antipsychotic
treatment change, while in the meantime there is substan-
tial differentiation of adverse events experienced by
patients under treatment for schizophrenia.
The present analysis aims at assessing treatment
changes made during the observation period of the study
and record the frequencies of treatment change due to
adverse event as well as other disease-related factors.
Materials and methods
The Grace study was a descriptive, cross-sectional, mul-
ticentre national survey conducted in the outpatient set-
ting by 104 psychiatrists, proportionally distributed
around Greece. Investigators registered one visit of each
of the first 20 consecutive patients that presented at
their consultation. Patient’s demographics, living status,
smoking status, alcohol consumption, blood laboratory
values, and data on the reasons leading to treatment
change during the past 6 months were recorded. Addi-
tionally, the reason and the antipsychotic drug selected
to carry on with, after the last treatment change were
also specified.
Results
The observational period was from June 2007 to June
2008 and led to the recruitment of 2013 patients with an
ICD-10 primary diagnosis of schizophrenia. Out of them
523 were being administered with a pharmacological
treatment against schizophrenia. This population subset
consisted of 51.6% men and 48.4% women, aged 39.9 ±
12.4 years. The mean number of treatment changes dur-
ing the past 6 months was 1.85 ± 1.58 times. According
to the investigators, the major adverse events that lead to
treatment change were extrapyramidal symptoms (44.7%),
weight gain (43.6%) and suppression (25%). For the most
recent treatment change, apart from adverse event occur-
rence (61%), other reasons that led to treatment change,
concomitantly present or not with adverse events, were
“no signs of improvement” (37%) and “clinical deteriora-
tion” (21%).
Conclusions
Adverse events occurrence remains an important reason
for treatment change in schizophrenic patients treated
with second generation antipsychotic agents. Extrapyra-
midal symptoms and weight gain are precarious adverse
events that should alert physicians for their early recog-
nition and management.
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